Key Highlights

• Innovodigm secures ₹5.5 Cr seed round led by IAN Group; proceeds fuel vaccine patch scalability and trials.
• Co‑founded by IIT‑Kharagpur alumni, micro‑array patch tech offers thermostable, needle‑free vaccines for remote regions.

Innovodigm, a medical technology startup, has raised Rs 5.5 crore in a seed round led by the IAN Group. PadUp Ventures invested the remaining Rs 4.5 crore, which IAN contributed.

Innovodigm said in a press release that the proceeds will be used for process optimization, infrastructure scaling, and team expansion to support third-party preclinical validation and preparation for upcoming clinical trials.

Innovodigm, founded in 2020 by Jhimli Manna and Ayan Chatterjee, develops micro-array patches for vaccines, providing a transformative alternative to traditional injectable immunizations. Designed to address issues such as cold-chain dependency, medical waste, and needle-stick injuries, the MAP employs thermostabilized vaccines that can last up to 120 days at 40°C, eliminating the need for refrigeration and allowing outreach to remote, underserved areas.

According to Innovodigm, the MAP platform has received significant recognition, including being named a Top 2 Technology at the Ministry of Electronics and Information Technology's Nano Electronics Showcase 2025. The company has signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer for third-party validation, and clinical trials are set to begin next year.

Also Read: Rahul Agarwal Appointed Partner to Lead HealthQuad VC Platform

"Spinning out of IIT Kharagpur's Microelectronics and MEMS Lab has been critical to our scientific foundation. Our MAP platform reflects India's ability to lead in affordable, scalable vaccine delivery that meets national and global public health objectives," said Jhimli Manna, CEO of Innovodigm.

Innovodigm plans to expand into India and other low- and middle-income countries, adapting its patch for a variety of vaccines such as measles, hepatitis, flu, and COVID-19 boosters. The company is also working to establish local manufacturing hubs so that patches can be produced closer to where they are needed the most.